Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
BEXSERO—an innovative vaccine developed to achieve a robust immune response1
BEXSERO works across age groups against a range of diverse MenB strains1
- MenB strains are highly variable in the types and amounts of antigens they express2
- By targeting four distinct antigens, BEXSERO offers the potential to protect against invasive MenB strains, even when the expression of one component is low or antigenically different134
- This multiple-antigen approach in BEXSERO may provide synergistic killing and improve strain coverage45
BEXSERO uniquely targets four distinct antigens—fHbp, NadA, PorA P1.4, and NHBA2
- Factor H binding protein (fHbp) binds factor H, which enables bacterial survival in the blood6
- Porin A (PorA) P1.4, part of outer membrane vesicles, has been shown to induce strain-specific bactericidal response7
- Neisseria heparin-binding antigen (NHBA) binds heparin, which may promote bacterial survival in the blood8
- Neisserial adhesion A (NadA) mediates binding to and entry into human epithelial cells9
MeNZB (BEXSERO) was developed by Chiron Vaccines in association with the Norwegian Institute of Public Health.7
Resources for parents
Here are 3 measures to approaching parents about prevention of MenB
References
- Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107(45):19490–19495.
- Bexsero Prescribing Information GDS 10/ Date: 09 November 2018.
- Medini D, Stella M, Wassil J. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33(23):2629–2636.
- Rappuoli R, Pizza M, Masignani V, Vadivelu K. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev Vaccines. 2018;17(12):1111–1121.
- Santolaya ME, O’Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study [published correction appears in Lancet. 2015 May 2;385(9979):1728]. Lancet. 2012;379(9816):617–624.
- Schneider MC, Prosser BE, Caesar JJE, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature. 2009;458(7240):890–893.
- Martin DR, Ruijne N, McCallum L, O’Hallahan J, Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol. 2006;13(4):486–491.
- Serruto D, Spadafina T, Ciucchi L, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA. 2010;107(8):3770–3775.
- Capecchi B, Adu-Bobie J, Di Marcello F, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol. 2005;55(3):687–698.
All mentioned products are registered in Saudi Arabia. This page may contain promotional content. For full prescribing information or adverse events reporting, please click on the relevant button in the header or footer of this page.
Trade marks are owned by or licensed to the GSK group of companies.
©2020 GSK group of companies or its licensor.
PM-SA-BEX-WCNT-200007 Date of preparation: September 2020
